Chemistry:List of estrogen esters

From HandWiki
Short description: None
Estradiol, the base estrogen of most estrogen esters.

This is a list of estrogen esters, or ester prodrugs of estrogens. It includes esters, as well as ethers, of steroidal estrogens like estradiol, estrone, and estriol and of nonsteroidal estrogens like the stilbestrols diethylstilbestrol and hexestrol.


Esters of steroidal estrogens

Estradiol esters

Marketed

Many esters of estradiol have been marketed, including the following major esters:[1][2]

And the following less commonly used esters:[1][2]

The following nitrogen mustard ester of estradiol is a cytostatic antineoplastic agent and has been marketed:[1][2]

Never marketed

A number of other estradiol esters which have not been marketed include:[2]

The following cytostatic antineoplastic nitrogen mustard esters of estradiol have not been marketed:[2]

  • Alestramustine (estradiol 3-(bis(2-chloroethyl)carbamate), 17-ester with L-alanine)
  • Atrimustine (KM-2210; bestrabucil, busramustine)
  • Estradiol mustard (NSC-112259; chlorphenacyl estradiol diester)
  • Estramustine (Leo 275; Ro 21-8837)
  • Estromustine (Leo 271 f; estrone 17β-3-N-bis(2-chloroethyl)carbamate, estrone–cytostatic complex)

Estrone esters

Marketed

Esters of estrone that have been marketed include:[1][2]

Never marketed

Other estrone esters which are notable but have not been marketed include:

Estriol esters

Marketed

Esters of estriol that have been marketed include:[1][2]

Never marketed

The following ester of estriol was never marketed:

Ethinylestradiol esters

Marketed

The following esters of ethinylestradiol exist and have been marketed:[1][2]

Never marketed

Esters of other steroidal estrogens

Marketed

The following esters of other estrogens exist and have been marketed:[1]

  • Hydroxyestrone diacetate (Colpoginon, Colpormon, Hormobion, Hormocervix) – the 3,16α-diacetate ester of 16α-hydroxyestrone

Ethers of steroidal estrogens

Marketed

A number of estrogen ethers also exist and have been marketed, including:[22][1]

  • Clomestrone (Arterolo, Atheran, Colesterel, Iposclerone, Liprotene, Persclerol) – the 3-methyl ether of 16α-chloroestrone
  • Cloxestradiol acetate (Genovul) – the O,O-diacetate ester of cloxestradiol (estradiol 17β-chloral hemiacetal ether)
  • Mestranol (Devocin, Ovastol, Tranel) (component of Enovid, Enavid, Ortho-Novin, Femigen, Norbiogest) – the 3-methyl ether of ethinylestradiol
  • Moxestrol (Surestryl) – the 11β-methoxy derivative of ethinylestradiol (and hence the 11β-methyl ether of the 11β-hydroxyl derivative of ethinylestradiol)
  • Nilestriol (Wei Ni An) – the 3-cyclopentyl ether of ethinylestriol
  • Promestriene (Colpotrofin, Colpotrophine, Delipoderm) – the 3-propyl and 17β-methyl diether of estradiol
  • Quinestradol (Colpovis, Colpovister, Pentovis) – the 3-cyclopentyl ether of estriol
  • Quinestrol (Agalacto-Quilea, Basaquines, Eston, Estrovis, Estrovister, Plestrovis, Qui-lea) – the 3-cyclopentyl ether of ethinylestradiol

Never marketed

A few other estrogen ethers which are notable but have not been marketed include:[22]

Esters of nonsteroidal estrogens

Diethylstilbestrol esters

Marketed

Major esters of diethylstilbestrol include:

  • Diethylstilbestrol dipropionate (Agostilben, Biokeral, Clinestrol, Cyclen, Estilbin, Estril, Neobenzoestrol, Orestol, Oroestrol, Ostregenin, Prostilbene, Stilbestriol DP, Stilboestrolum Dipropionicum, Stilboestrol, Synestrin, Willestrol)
  • Fosfestrol (diethylstilbestrol diphosphate) (Honvan, Difostilben, Fosfostilben, Fostrolin, Stilbol, Stilphostrol, Vagestrol)

Less commonly used esters of diethylstilbestrol include:

Never marketed

As well as the following nitrogen mustard ester:

  • ICI-85966 (Stilbostat; diethylstilbestrol bis(di(2-chloroethyl)carbamate))

Hexestrol esters

Marketed

Never marketed

The following nitrogen mustard ester of hexestrol was never marketed:

  • Phenestrol (fenestrol; hexestrol bis[4-[bis(2-chloroethyl)amino]phenylacetate)

Esters of other nonsteroidal estrogens

Marketed

Ethers of nonsteroidal estrogens

Diethylstilbestrol

Marketed

  • Diethylstilbestrol monobenzyl ether (benzelstilbestrol) (Monozol, Hypantin, Pituitrope)
  • Dimestrol (dianisylhexene, diethylstilbestrol dimethyl ether, dimethoxydiethylstilbestrol) (Depot-Ostromon, Synthila)
  • Mestilbol (diethylstilbestrol monomethyl ether) (Monomestro or Monomestrol)

See also

References

  1. 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 IndexNominum2000. Taylor & Francis US. 2000. p. 404. ISBN 978-3-88763-075-1. https://books.google.com/books?id=5GpcTQD_L2oC&pg=PA404. Retrieved 29 May 2012. 
  2. 2.0 2.1 2.2 2.3 2.4 2.5 2.6 2.7 A. D. Roberts (1991). Dictionary of Steroids: Chemical Data, Structures, and Bibliographies. CRC Press. p. 415. ISBN 978-0-412-27060-4. https://books.google.com/books?id=qw5X0NK1A90C&pg=PA415. Retrieved 20 May 2012. 
  3. Ferin, J. (1952). "Relative duration of action of natural and synthetic estrogens administered parenterally in women with estrogen deficiency". The Journal of Clinical Endocrinology & Metabolism 12 (1): 28–35. doi:10.1210/jcem-12-1-28. ISSN 0021-972X. PMID 14907837. 
  4. "R&D Research". http://www.evestra.com/index-Dateien/Page1242.htm. 
  5. "Estradiol prodrugs (EP) for efficient oral estrogen treatment and abolished effects on estrogen modulated liver functions". J. Steroid Biochem. Mol. Biol. 165 (Pt B): 305–311. January 2017. doi:10.1016/j.jsbmb.2016.07.008. PMID 27449818. 
  6. "A prodrug design for improved oral absorption and reduced hepatic interaction". Bioorg. Med. Chem. 25 (20): 5569–5575. October 2017. doi:10.1016/j.bmc.2017.08.027. PMID 28886996. 
  7. Nickisch, K., Santhamma, B., Ahmed, G., Meece, F., Elger, W., Wyrwa, R., & Nair, H. (2017). U.S. Patent No. 9,745,338. Washington, DC: U.S. Patent and Trademark Office. https://patents.google.com/patent/US9745338B2/en
  8. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans; World Health Organization; International Agency for Research on Cancer (2007). Combined Estrogen-progestogen Contraceptives and Combined Estrogen-progestogen Menopausal Therapy. World Health Organization. pp. 388–. ISBN 978-92-832-1291-1. https://books.google.com/books?id=aGDU5xibtNgC&pg=PA388. 
  9. Vizzone, A.; Murari, G. (November 1966). "[Estradiol esters (3-monobenzoate and 3-benzoate-17-beta-acetate) in the therapy of the surgical menopause syndrome. Experimental and clinical results]". Quaderni di Clinica Ostetrica e Ginecologica 21 (11): 779–790. PMID 5999221. 
  10. 10.0 10.1 10.2 "Prodrugs for improved oral beta-estradiol bioavailability". Pharm. Res. 5 (1): 44–7. January 1988. doi:10.1023/A:1015863412137. PMID 3244608. 
  11. 11.0 11.1 11.2 Lokind, Kenneth B.; Lorenzen, Finn Hjort; Bundgaard, Hans (1991). "Oral bioavailability of 17β-estradiol and various ester prodrugs in the rat". International Journal of Pharmaceutics 76 (1–2): 177–182. doi:10.1016/0378-5173(91)90356-S. ISSN 0378-5173. 
  12. 12.0 12.1 "Oral long-lasting estrogenic activity of estradiol 3-benzoate 17-cyclooctenyl ether". Steroids 20 (5): 627–38. November 1972. doi:10.1016/0039-128X(72)90020-7. PMID 4654978. 
  13. "Effect of two orally active estradiol derivatives on sulfobromphthalein retention in rats". Pharmacol Res Commun 6 (2): 135–45. April 1974. doi:10.1016/s0031-6989(74)80021-4. PMID 4438394. 
  14. Ralph I. Dorfman (5 December 2016). Steroidal Activity in Experimental Animals and Man. Elsevier Science. pp. 36–. ISBN 978-1-4832-7299-3. https://books.google.com/books?id=BbLfBAAAQBAJ&pg=PA36. 
  15. Janocko, Laura; Larner, Janice M.; Hochberg, Richard B. (1984). "The Interaction of C-17 Esters of Estradiol with the Estrogen Receptor*". Endocrinology 114 (4): 1180–1186. doi:10.1210/endo-114-4-1180. ISSN 0013-7227. PMID 6705734. 
  16. "Oral replacement with estradiol-cyclooctyl acetate: a new estradiol analogue. Effects on serum lipids, proteins, gonadotrophins, estrogens and uterine endometrial morphology". Gynecol. Obstet. Invest. 20 (2): 84–90. 1985. doi:10.1159/000298978. PMID 3932144. 
  17. "Effects of estradiol decanoate in ovariectomized women". J. Endocrinol. Invest. 1 (2): 101–6. 1978. doi:10.1007/BF03350355. PMID 755846. 
  18. 18.0 18.1 "The duration of activity of the benziloyl hydrazones of testosterone-17-heptanoate, estrone-3-heptanoate and 17α-hydroxy-progesterone-17-heptanoate". Endocrinology 65 (3): 508–511. 1959. doi:10.1210/endo-65-3-508. ISSN 0013-7227. PMID 13828402. 
  19. George W.A Milne (8 May 2018). Drugs: Synonyms and Properties: Synonyms and Properties. Taylor & Francis. pp. 1406–. ISBN 978-1-351-78989-9. https://books.google.com/books?id=xUlaDwAAQBAJ&pg=PT1406. 
  20. 20.0 20.1 "Novel oestrogen sulfamates: a new approach to oral hormone therapy". Expert Opin Investig Drugs 7 (4): 575–89. April 1998. doi:10.1517/13543784.7.4.575. PMID 15991994. 
  21. "Sulfamates of various estrogens are prodrugs with increased systemic and reduced hepatic estrogenicity at oral application". J. Steroid Biochem. Mol. Biol. 55 (3–4): 395–403. December 1995. doi:10.1016/0960-0760(95)00214-6. PMID 8541236. 
  22. 22.0 22.1 J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. ISBN 978-1-4757-2085-3. https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PR2. 
  23. "A prodrug approach to increasing the oral potency of a phenolic drug. 1. Synthesis, characterization, and stability of an O-(imidomethyl) derivative of 17 beta-estradiol". J Pharm Sci 83 (10): 1477–81. October 1994. doi:10.1002/jps.2600831022. PMID 7884673. 
  24. "A prodrug approach to increasing the oral potency of a phenolic drug. Part 2. Pharmacodynamics and preliminary bioavailability of an orally administered O-(imidomethyl) derivative of 17 beta-estradiol". J Pharm Sci 84 (2): 174–8. February 1995. doi:10.1002/jps.2600840210. PMID 7738796. 
  25. 25.0 25.1 Thomas L. Lemke; David A. Williams (24 January 2012). Foye's Principles of Medicinal Chemistry. Lippincott Williams & Wilkins. pp. 1395–. ISBN 978-1-60913-345-0. https://books.google.com/books?id=Sd6ot9ul-bUC&pg=PA1395.